Editorial: Future frontiers in the management of metastatic colorectal cancer.

The editorial discusses the challenges in managing metastatic colorectal cancer (mCRC) and the need for innovative treatments due to a low five-year survival rate. Recent advancements in treatment, such as the combination of Trifluridine and Tipiracil with bevacizumab, have shown promise in improving outcomes for patients. The article also highlights the importance of surgical interventions, including minimally invasive techniques, in treating mCRC with liver involvement. Additionally, the text emphasizes the significance of personalized medicine and immunotherapy in transforming the future of mCRC treatment. [Extracted from the article]